Apparent Diffusion Coefficient is a Useful Biomarker for Monitoring Adipose-Derived Mesenchymal Stem Cell Therapy of Renal Ischemic-Reperfusion Injury.
Ko SF., Yip HK., Lee CC., Lee CC., Su CH., Huang CC.
Animal Study on Chronic Kidney Disease, published in Mol Imaging Biol (2018) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Mol Imaging Biol (2018)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 29549575
- DOI
- 10.1007/s11307-018-1184-0
Abstract (original English)
This study aimed to investigate the potential of apparent diffusion coefficient (ADC) for monitoring adipose-derived mesenchymal stem cell (ADMSC) therapy of renal ischemic-reperfusion injury (IRI). After baseline magnetic resonance imaging (MRI), 36 Sprague-Dawley rats with bilateral renal IRI were divided equally as groups 1, 2, and 3 (non-treated rats) and groups 4, 5, and 6 (ADMSC-treated rats, with 2 million ADMSCs injected via the tail vein at 6 h after IRI). Groups 1 and 4, 2 and 5, and 3 and 6 were euthanized at days 1, 3, and 7, respectively, after renal MRI. The ratios of ADC at different time points to baseline values in the cortex, outer, and inner stripes of outer medulla (OSOM/ISOM), assessments of monocyte chemoattractant protein-1 (MCP-1), CD68+ cells, tubular cast formation, and degree of fibrosis in three zones over time were compared between the non-treated and ADMSC-treated rats. Among three zones, the differences in cortical ADC and immunohistochemical changes between the non-treated and ADMSC-treated IRI rats over time were less obvious. Compared with the non-treated rats, the ADMSC-treated rats exhibited significantly higher ADC ratios of OSOM and ISOM at days 1 and 3 corresponding to significantly less MCP-1 staining, CD68+ cells, and tubular casts. From day 3 to day 7, coupling with the decrement of MCP-1 and CD68+ cells in IRI kidneys, the effect of ce
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review
Systematic Review on Chronic Kidney Disease, published in Ren Fail (2026) — summary generated from the PubMed abstract.
- 2026
Ren Fail - Level AMeta-analysisEurope PMC
Meta-analysis study of the therapeutic impact of Mesenchymal stem cells derived exosomes for chronic kidney diseases
Meta-analysis on Chronic Kidney Disease, published in Biochem Biophys Rep (2025) — summary generated from the PubMed abstract.
- 2025
Biochem Biophys Rep2 citations - Level ASystematic ReviewPubMed
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Systematic Review with a reported sample of 953 on Osteoarthritis, Chronic Kidney Disease, Scar, Autoimmune Research, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
- n = 953
Int J Mol Sci2 citations - Level ASystematic ReviewEurope PMC
Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024
Systematic Review on Chronic Kidney Disease, Acute Kidney Injury, published in Front Immunol (2025) — summary generated from the PubMed abstract.
- 2025
Front Immunol2 citations - Level AMeta-analysisEurope PMC
Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Meta-analysis on Chronic Kidney Disease, Chronic Inflammation, published in Cells (2025) — summary generated from the PubMed abstract.
- 2025
Cells - Level AMeta-analysisEurope PMC
Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis
Meta-analysis on Chronic Kidney Disease, Acute Kidney Injury, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol1 citations